Brief: Prelude Therapeutics Provides Clinical Update
09/03/2022 13:19
March 9 (Reuters) - Prelude Therapeutics Inc PRLD.O :
* PRELUDE THERAPEUTICS PROVIDES CLINICAL UPDATE AND ANNOUNCES PRESENTATION
OF NEW
PRECLINICAL DATA AT THE UPCOMING 2022 AACR ANNUAL MEETING
* PRELUDE THERAPEUTICS INC - ANNOUNCES STRATEGIC PRIORITIZATION WITHIN LEAD
PROGRAMS TARGETING PRMT5 AND MCL1
* PRELUDE THERAPEUTICS INC - ADVANCES PRT2527, WITH GOAL OF ESTABLISHING A
RECOMMENDED PHASE 2 DOSE IN 2H/2022
* PRELUDE THERAPEUTICS - PROGRESSES HIGHLY SELECTIVE POTENTIAL
FIRST-IN-CLASS
SMARCA2/BRM DEGRADER WITH IND SUBMISSION PLANNED BY YEAR-END 2022
Source text for Eikon: ID:nGNX73Gv90
Further company coverage: PRLD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Prelude Therapeutics Incorporated
See all newsBrief: Prelude Announces Clinical Trial Collaboration And Supply Agreement With Lilly To Evaluate KAT6A Selective Degrader PRT13722 In Combination With Verzenio® And Inluriyo® In Patients With HR+/HER2- Breast Cancer
U.S. RESEARCH ROUNDUP-Celcuity, Fluence Energy, Salesforce
Prelude Therapeutics Incorporated reports results for the quarter ended June 30 - Earnings Summary
Prelude Therapeutics Q2 revenue beats analyst expectations, net loss narrows
Prelude Therapeutics Incorporated expected to post a loss of 20 cents a share - Earnings Preview